Experimental drug targets Hard-to-Treat cancers, but trial ends early
Disease control
Terminated
This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC